Inmazeb Injection, Solution
Product Images NDC 61755-019

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Inmazeb (NDC 61755-019). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Regeneron Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Inmazeb 01)

FDA Label Image

Principal Display Panel (14.5 mL Vial Carton)

This is a description of a medication called Inmazeb. Each vial contains 241.7mg of atoltivimab, 241.7mg of maftivimab, and 241.7mg of odesivimab. The medication is to be administered intravenously after dilution. The solution shouldn't be frozen or shaken and must be stored at 2°C to 8°C (36°F to 46°F) in the original carton to protect it from light. Any unused portion of the solution should be discarded.*

FDA Label Image

Inmazeb 03

This text describes a medication called Inmazeb that comes in a single-dose vial containing 483.3 mg of atoltivimab, maftivimab, and odesivimab. It should be injected intravenously after dilution as advised in the prescribing information. One can check the expiry date by scanning a QR code or visiting a specific website. The medication must be refrigerated and protected from light. The carton comes with a single-dose vial and prescribing information, and unused portions should be discarded. If the seal is broken or missing, do not use the vial.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.